Skip to main content
SpringerLink
Log in

Dosimetry for 131I mIBG Therapy

  • Chapter
  • First Online:
Clinical Applications of Nuclear Medicine Targeted Therapy

  • 985 Accesses

Abstract

In 131I-mIBG of paediatric neuroblastoma, the first dosimetric method introduced was whole-body dosimetry by Lashford et al. (J Clin Oncol 10(12):1889–96, 1992). This aims to prevent haematological toxicity. Despite its simplicity and level of approximation, this method is the basis for a forthcoming European multicentre trial, in which the activity of a second administration is planned according to the whole-body absorbed dose delivered in the first. Lesion dosimetry has also been performed, though in a small number of centres. The limited number of lesion dosimetry studies derives from the challenge of high activity quantitative imaging of I-131, incurring gamma camera saturation in peri-therapy imaging, and the need for children to remain steady during sequential camera scans. The major goal now is to establish absorbed dose-effect correlation studies, which will provide a fundamental basis for individualised treatment planning. Thanks to the improvement of methods for internal dosimetry and radiobiology over the last two decades and the increasing availability of quantitative 124I PET imaging, in the near future, we could have a more systematic basis for standardisation and individualisation of mIBG therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Castellani MR, Seghezzi S, Chiesa C, Aliberti GL, Maccauro M, Seregni E, et al. 131I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy. Q J Nucl Med Mol Imaging. 2010;54(1):100–13.

    CAS  PubMed  Google Scholar 

  2. Sisson JC, Hutchinson RJ, Carey JE, Shapiro B, Johnson JW, Mallette SA, Wieland DM. Toxicity from treatment of neuro-blastoma with 131I-meta-Iodobenzylguanidine. Eur J Nucl Med. 1988;14(7-8):337–40.

    CAS  PubMed  Google Scholar 

  3. Fielding SL, FLower MA, Ackery D, Kemshead JT, Lashford LS, Lewis I. Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study. Eur J Nucl Med. 1991;18:308–16.

    Article  CAS  PubMed  Google Scholar 

  4. Monsieurs M, Brans B, Bacher K, Dierckx R, Thierens H. Patient dosimetry for I-131-MIBG therapy for neuroendocrine tumours based on I-123-MIBG scans. Eur J Nucl Med Mol Imaging. 2002;29(12):1581–7.

    Article  CAS  PubMed  Google Scholar 

  5. Flux GD, Guy MJ, Beddows R, Pryor M, Flower MA. Estimation and implications of random errors in whole-body dosimetry for targeted radionuclide therapy. Phys Med Biol. 2002;47(17):3211–23.

    Article  PubMed  Google Scholar 

  6. Buckley SE, Chittenden SC, Saran FH, Meller ST, Flux GD. Whole-body dosimetry for individualized treatment planning of 131I-mIBG radionuclide therapy for neuroblastoma. J Nucl Med. 2009;50(9):1518–24.

    Article  CAS  PubMed  Google Scholar 

  7. Chittenden S, Pratt B, Pomeroy K, Black P, Long C, Smith N, Buckley SE, Saran F, Flux GD. Optimization of equipment and methodology for whole-body activity retention measurements in children undergoing targeted radionuclide therapy. Cancer Biother Radiopharm. 2007;22(2):247–53.

    Article  Google Scholar 

  8. Dewaraja YK, Ljungberg M, Green AJ, Zanzonico PB, Frey EC, SNMMI MIRD Committee, Bolch WE, Brill AB, Dunphy M, Fisher DR, Howell RW, Meredith RF, Sgouros G, Wessels BW. MIRD pamphlet no. 24: guidelines for quantitative 131I SPECT in dosimetry applications. J Nucl Med. 2013;54(12):2182–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Gaze MN, Chang YC, Flux GD, Mairs RJ, Saran FH, Meller ST. Feasibility of dosimetry-based high-dose131i-meta-Iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm. 2005;20(2):195–9.

    Article  CAS  PubMed  Google Scholar 

  10. Matthay KK, DeSantes K, Hasegawa B, Huberty J, Hattner RS, Ablin A, et al. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol. 1998;16(1):229–36.

    Article  CAS  PubMed  Google Scholar 

  11. Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med. 2001;42(11):1713–21.

    CAS  PubMed  Google Scholar 

  12. Hartung-Knemeyer V, Rosenbaum-Krumme S, Buchbender C, Poppel T, Brandau W, Jentzen W, et al. Malignant pheochromocytoma imaging with [124I]mIBG PET/MR. J Clin Endocrinol Metab. 2012;97(11):3833–4.

    Article  CAS  PubMed  Google Scholar 

  13. Ott RJ, Tait D, Flower MA, Babich JW, Lambrecht RM. Treatment planning for 131I mIBG radiotherapy of neural crest tumors using 124I-mIBG positron emission tomography. Br J Radiol. 1992;65:787–91.

    Article  CAS  PubMed  Google Scholar 

  14. Hindorf C, Glatting G, Chiesa C, Lindèn O, Flux G. EANM dosimetry committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37(6):1238–5.

    Article  PubMed  Google Scholar 

  15. Chiesa C, Castellani R, Mira M, Lorenzoni A, Flux GD. Dosimetry in 131I-MIBG therapy: moving toward personalized medice. Q J Nucl Med Mol Imaging. 2013;57:161–70.

    CAS  PubMed  Google Scholar 

  16. Lashford LS, Lewis IJ, Fielding SL, Flower MA, Meller S, Kemshead JT, Ackery D. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children’s Cancer Study Group investigation. J Clin Oncol. 1992;10(12):1889–96.

    Article  CAS  PubMed  Google Scholar 

  17. Koral KF, Huberty JP, Frame B, Matthay KK, Maris JM, Regan D, et al. Hepatic absorbed radiation dosimetry during 131I metaiodobenzylguanidine (MIBG) therapy for refractory neuroblastoma. Eur J Nucl Med Mol Imaging. 2008;35:2105–12.

    Article  CAS  PubMed  Google Scholar 

  18. Flux GD, Chittenden SJ, Saran F, Gaze MN. Clinical applications of dosimetry for mIBG therapy. Q J Nucl Med Mol Imaging. 2011;55:116–25.

    CAS  PubMed  Google Scholar 

  19. Tristam M, Alaamer AS, Fleming JS, Lewington VJ, Zivanovic MA. Iodine-131-metaiodobenzylguanidine dosimetry in cancer therapy: risk versus benefit. J Nucl Med. 1996;37(6):1058–63.

    CAS  PubMed  Google Scholar 

  20. Sudbrock F, Schmidt M, Simon T, Eschner W, Berthold F, Schica H. Dosimetry for 131I mIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2010;37:1279–90.

    Google Scholar 

  21. Delpon G, Ferrer L, Lisbona A, Bardies M. Correction of count losses due to deadtime on a DST-XLi (SMVi-GE) camera during dosimetric studies in patients injected with iodine-131. Phys Med Biol. 2002;47:N79–90.

    Article  CAS  PubMed  Google Scholar 

  22. Chiesa C, Negri A, Albertini C, Azzeroni R, Setti E, Mainardi L, Aliberti G, Seregni E, Bombardieri E. A practical dead time correction method in planar activity quantification for dosimetry during radionuclide therapy. Q J Nucl Med Mol Imaging. 2009;53(6):658–70.

    CAS  PubMed  Google Scholar 

  23. Buckley SE, Saran FH, Gaze MN, Chittenden S, Partridge M, Lancaster D, Pearson A, Flux GD. Dosimetry for fractionated 131I-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results. Cancer Biother Radiopharm. 2007;22(1):105–12.

    Article  CAS  PubMed  Google Scholar 

  24. Huang S, Bolch WE, Lee C, Brocklin H, Pampaloni M, Hawkins R, Sznewajs A, DuBois S, Matthay K, Seo Y. Patient-specific dosimetry using pretherapy [124I]m-iodobenzylguanidine ([124I]mIBG) dynamic PET/CT imaging before [131I]mIBG targeted radionuclide therapy for neuroblastoma. Mol Imaging Biol. 2015;17:284–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

    Carlo Chiesa

  2. Joint Department of Physics, Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK

    Glenn Flux

Authors
  1. Carlo Chiesa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Glenn Flux
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlo Chiesa .

Editor information

Editors and Affiliations

  1. Department of Nuclear Medicine, Humanitas Gavazzeni Hospital, Bergamo, Italy

    Emilio Bombardieri

  2. Nuclear Medicine Therapy and Endocrinology, Istituto Nazionale dei Tumori, Milano, Italy

    Ettore Seregni

  3. Nuclear Medicine and Molecular Imaging Unit, Veneto Institute of Oncology IOV - IRCCS, Padova, Italy

    Laura Evangelista

  4. Nuclear Medicine Division, Istituto Nazionale dei Tumori, Milano, Italy

    Carlo Chiesa

  5. Nuclear Medicine, Humanitas Research Hospital, Rozzano, Milano, Italy

    Arturo Chiti

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Chiesa, C., Flux, G. (2018). Dosimetry for 131I mIBG Therapy. In: Bombardieri, E., Seregni, E., Evangelista, L., Chiesa, C., Chiti, A. (eds) Clinical Applications of Nuclear Medicine Targeted Therapy . Springer, Cham. https://doi.org/10.1007/978-3-319-63067-0_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-63067-0_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-63066-3

  • Online ISBN: 978-3-319-63067-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation